Johnson & Johnson (JNJ) — Analysis Summary
Johnson & Johnson (JNJ) has a market cap of $622.84B with year-over-year revenue growth of +6.0%. Net margin stands at 28.5%. The stock trades at a P/E ratio of 29.6.
Key Takeaways
- Revenue changed +6.0% year-over-year
- Net margin of 28.5%
- P/E ratio of 29.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, JNJ posted revenue growth of +6.0% and trades at a P/E of 29.6.
Johnson & Johnson (JNJ)
PREVIOUS CLOSE 2026-10-08 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
140,800
Headquarters
NEW BRUNSWICK, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$5.36
Dividend Yield
2.09%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.